Exploiting cancer cell cycling for selective protection of normal cells

Cancer Research

Volumn 61, Issue 11, 2001, Pages 4301-4305

  Blagosklonny, M V ^a   Pardee, A B ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER GROWTH FACTOR; PROTEIN P16; PROTEIN P53; RETINOBLASTOMA PROTEIN;

CANCER CELL; CANCER CELL DESTRUCTION; CANCER CHEMOTHERAPY; CANCER INHIBITION; CELL CYCLE; CELL PROTECTION; CYTOTOXICITY; HUMAN; HUMAN CELL; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; TARGET CELL;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL CYCLE; CELL DIVISION; HUMANS; NEOPLASMS;

EID: 0035359505     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (99)

1. The retinoblastoma protein and cell cycle control
2. Oncoprotein networks
3. Cancer cell cycles
4. CDK inhibitors: Positive and negative regulators of G1-phase progression
5. The hallmarks of cancer
6. Anticancer drug targets: Growth factors and growth factor signaling
7. Choosing anticancer drug targets in the postgenomic era
8. Apoptosis and cancer drug targeting
9. Anticancer drug targets: Cell cycle and checkpoint control
10. Tyrosine kinase inhibition: An approach to drug development
11. A synthetic inhibitor of the mitogen-activated protein kinase cascade
12. Therapeutic application of anti-growth factor receptors antibodies
13. Preclinical and clinical development of cyclin-dependent kinase modulators
14. Immunoconjugates of geldanamycin and anti-HER2 monoclonal antibodies: Antiproliferative activity on human breast carcinoma cell lines
15. Lessons learned from the development of an Ab1 tyrosine inhibitor for chronic myelogenous leukemia
16. Geldanamycin selectively destabilizes and conformationally alters mutated p53
17. Restoration of the growth suppression function of mutant p53 by a synthetic peptide derived from the p53 C-terminal domain
18. Pharmacological rescue of mutant p53 conformation and function
19. Inhibition of telomerase limits the growth of human cancer cells
20. Phase I clinical and pharmacokinetic study of oral carboxyamidotriazole, a signal transduction inhibitor
21. Phase I and pharmacologic study of the tyrosine kinase inhibitor SU101 in patients with advanced solid tumors
22. A Phase II study of high-dose tamoxifen in patients with hormone- refractory prostate cancer
23. Cardiotoxicity in patients receiving transtuzumab (Herceptin): Primary toxicity, synergistic or sequential stress, or surveillance artifact?
24. Flavopiridol, a novel cyclin-dependent kinase inhibitor, in metastatic renal cancer: A University of Chicago Phase II Consortium study
25. Codominant interference, antieffectors, and multitarget drugs
26. WAF1/CIP1, Rb, and c-myc signaling in phorbol ester-resistant cancer cells
27. Induction of apoptosis in fibroblasts by c-myc protein
28. Oncogenes and the strategy of growth factors
29. A matter of life and cell death
30. A node between proliferation, apoptosis, and growth arrest
31. Tossing monkey wrenches into the clock: New ways of treating cancer
32. Apoptosis in cancer
33. Dysregulation of apoptosis in cancer
34. Uncoupling of S phase and mitosis induced by anticancer agents in cells lacking p21
35. Requirement for p53 and p21 to sustain G2 arrest after DNA damage
36. Deficiency of retinoblastoma protein leads to inappropriate S-phase entry, activation of E2F-responsive genes, and apoptosis
37. Abrogation of the G2 cell cycle checkpoint associated with overexpression of HSIXI: A possible mechanism of breast carcinogenesis
38. Loss of normal p53 function confers sensitization to Taxo1 by increasing G2/M arrest apoptosis
39. Disruption of p53 in human cancer cells alters the responses to therapeutic agents
40. Defective G1-S cell cycle checkpoint function sensitizes cells to microtubule inhibitor-induced apoptosis
41. Apoptosis in cancer therapy: Crossing the threshold
42. p53, cell cycle control and apoptosis: Implications for cancer
43. Mechanism by which caffeine potentiates lethality of nitrogen mustard
44. Abolition by cycloheximide of caffeine-enhanced lethality of alkylating agents in hamster cells
45. Caffeine-induced uncoupling of mitosis from the completion of DNA replication in mammalian cells
46. In vivo and in vitro enhanced antitumor effects by pentoxifylline in human cancer cells treated with thiotepa
47. UCN-01, a potent abrogator of G2 checkpoint function in cancer cells with disrupted p53
48. UCN-01 abrogates G2 arrest through a Cdc2-dependent pathway that is associated with inactivation of the Wee I Hu kinase and activation of the Cdc25C phosphatase
49. UCN-01 (7-hydroxystaurosporine) and other indolocarbazole compounds: A new generation of anti-cancer agents for the new century?
50. An indolocarbazole inhibitors of human checkpoint kinase (Chkl) abrogates cell cycle arrest caused by DNA damage
51. Cell cycle control and cancer
52. The DNA damage response: Putting checkpoints in perspective
53. A long twentieth century of the cell cycle and beyond
54. Selective killing of transformed baby hamster kidney (BHK) cells
55. Histidinol-mediated improvement in the specificity of 1-β-D-arabinofuranosylcytosine and 5-fluorouracil in L1210-leukemia-bearing mice
56. Differential protection of normal and malignant human myeloid progenitors (CFU-GM) from Ara-C toxicity using cycloheximide
57. Enhancement of anticancer agent activity by selective inhibition of rapidly proliferating tissues of the host
58. Sequence-dependent antagonism between fluorouracil and paclitaxel in human breast cancer cells
59. Sequence-dependent hematological toxicity associated with the 3-hour paclitaxel/cyclophosphamide doublet
60. Superiority of sequential versus concurrent administration of paclitaxel with etoposide in advanced non-small cell lung cancer: Comparison of two phase II trials
61. Effects of p21(Cip1/Waf1) at both the G1/S and the G2/M cell cycle transitions: pRb is a critical determinant in blocking DNA replication and in preventing endoreduplication
62. p53 regulation of G2 checkpoint is retinoblastoma protein dependent
63. Cooperative effects of genes controlling the G2/M checkpoint
64. Pretreatment with DNA-damaging agents permits selective killing of checkpoint-deficient cells by microtubule-active drugs
65. Role of p53 and p21waf1/cip1 in senescence-like terminal proliferation arrest induced in human tumor cells by chemotherapeutic drugs
66. A reversible, p53-dependent G0/G1 cell cycle arrest induced by ribonucleotide depletion in the absence of detectable DNA damage
67. A p53-dependent S-phase checkpoint helps to protect cells from DNA damage in response to starvation for pyrimidine nucleotides
68. The complexity of p53 modulation: Emerging patterns from divergent signals
69. The G2 checkpoint is maintained by redundant pathways
70. The Chkl protein kinase and the Cdc25C regulatory pathways are targets of the anticancer agent UCN-01
71. Loss of epidermal growth factor requirement and malignant transformation
72. Loss of cell cycle control allows selective microtubule drug-induced Bcl-2 phosphorylation and cytotoxicity in highly autonomous cancer cells
73. Reversible G1 arrest induced by inhibition of the epidermal growth factor receptor tyrosine kinase requires up-regulation of p27K1P1 independent of MAPK activity
74. Comparison of ability of protein kinase C inhibitors to arrest cell growth and to alter cellular protein kinase C localisation
75. G1 phase accumulation induced by UCN-01 is associated with dephosphorylation of Rb and CDK2 proteins as well as induction of CDK inhibitor p21/ Cip1/WAF1/Sdi1 in p53-mutated human epidermoid carcinoma A431 cells
76. Transformed mammalian cells are deficient in kinase-mediated control of progression through the G1 phase of the cell cycle
77. Different effects of staurosporine, an inhibitor of protein kinases, on the cell cycle and chromatin structure of normal and leukemic lymphocytes
78. Apoptosis in antitumor strategies: Modulation of cell-cycle or differentiation
79. Protection of normal proliferating cells against chemotherapy by staurosporine-mediated, selective, and reversible G1 arrest
80. Transforming growth factor-β3 protection of epithelial cells from cycle-selective chemotherapy in vitro
81. Recombinant transforming growth factor β1 and β2 protect mice from acutely lethal doses of 5-fluorouracil and doxorubicin
82. Transforming growth factor-β3 protects murine small intestinal crypt stem cells and animal survival after irradiation, possibly by reducing stem-cell cycling
83. Transforming growth factor-β3 mediated modulation of cell cycling and attenuation of 5-fluorouracil induced oral mucositis
84. Resistance to apoptosis conferred by Cdk inhibitors during myocyte differentiation
85. Reversible, p16-mediated cell cycle arrest as protection from chemotherapy
86. Overexpression of p21 (waf1) decreases G2-M arrest and apoptosis induced by paclitaxel in human sarcoma cells lacking both p53 and functional Rb protein
87. Differential modulation of paclitaxel-mediated apoptosis by p21(Waf1) and p27(Kip1)
88. Role of the p16 tumor suppressor gene in cancer
89. Hyperinducibility of hypoxia-responsive genes without p53/p21-dependent checkpoint in aggressive prostate cancer
90. The Pezcoller lecture: Cancer cell cycle revisited
91. Prevention of chemotherapy-induced alopecia in rats by CDK inhibitors
92. pRB plays an essential role in cell cycle arrest induced by DNA damage
93. RB status as a determinant of response to UCN-01 in non-small cell lung carcinoma
94. Comparison of the effectiveness of adenovirus vectors expressing cyclin kinase inhibitors p16INK4A, p18INK4C, p19INK4D, p21 (WAF1/CIP1) and p27KIP1 in inducing cell cycle arrest, apoptosis and inhibition of tumorigenicity
95. Drug-resistance enables selective killing of resistant leukemia cells: Exploiting of drug resistance instead of reversal
96. A chemical inhibitor of p53 that protects mice from the side effects of cancer therapy
97. Antitumor activity of UCN-01, a selective inhibitor of protein kinase C, in murine and human tumor models
98. Tumor angiogenesis: Therapeutic implications